Logo image of MYGN

MYRIAD GENETICS INC (MYGN) Stock Fundamental Analysis

NASDAQ:MYGN - Nasdaq - US62855J1043 - Common Stock - Currency: USD

7.42  +0.05 (+0.68%)

After market: 7.42 0 (0%)

Fundamental Rating

3

MYGN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. MYGN may be in some trouble as it scores bad on both profitability and health. MYGN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year MYGN was profitable.
MYGN had a negative operating cash flow in the past year.
In the past 5 years MYGN always reported negative net income.
In multiple years MYGN reported negative operating cash flow during the last 5 years.
MYGN Yearly Net Income VS EBIT VS OCF VS FCFMYGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

MYGN has a better Return On Assets (-11.73%) than 85.89% of its industry peers.
MYGN's Return On Equity of -17.19% is amongst the best of the industry. MYGN outperforms 87.65% of its industry peers.
Industry RankSector Rank
ROA -11.73%
ROE -17.19%
ROIC N/A
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
MYGN Yearly ROA, ROE, ROICMYGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

The Gross Margin of MYGN (69.89%) is better than 81.13% of its industry peers.
MYGN's Gross Margin has declined in the last couple of years.
MYGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
MYGN Yearly Profit, Operating, Gross MarginsMYGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MYGN has been increased compared to 1 year ago.
Compared to 5 years ago, MYGN has more shares outstanding
Compared to 1 year ago, MYGN has a worse debt to assets ratio.
MYGN Yearly Shares OutstandingMYGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
MYGN Yearly Total Debt VS Total AssetsMYGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

MYGN has an Altman-Z score of 0.96. This is a bad value and indicates that MYGN is not financially healthy and even has some risk of bankruptcy.
MYGN has a better Altman-Z score (0.96) than 67.72% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that MYGN is not too dependend on debt financing.
The Debt to Equity ratio of MYGN (0.05) is worse than 62.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 0.96
ROIC/WACCN/A
WACC10.11%
MYGN Yearly LT Debt VS Equity VS FCFMYGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

MYGN has a Current Ratio of 1.96. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.96, MYGN is doing worse than 75.84% of the companies in the same industry.
MYGN has a Quick Ratio of 1.78. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.78, MYGN is doing worse than 77.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.78
MYGN Yearly Current Assets VS Current LiabilitesMYGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 146.43% over the past year.
MYGN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 86.63% yearly.
The Revenue has grown by 11.21% in the past year. This is quite good.
Measured over the past years, MYGN shows a decrease in Revenue. The Revenue has been decreasing by -0.32% on average per year.
EPS 1Y (TTM)146.43%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)11.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%7.12%

3.2 Future

The Earnings Per Share is expected to grow by 33.97% on average over the next years. This is a very strong growth
Based on estimates for the next years, MYGN will show a small growth in Revenue. The Revenue will grow by 5.25% on average per year.
EPS Next Y-39.33%
EPS Next 2Y45.76%
EPS Next 3Y53.71%
EPS Next 5Y33.97%
Revenue Next Year0.79%
Revenue Next 2Y4.51%
Revenue Next 3Y5.51%
Revenue Next 5Y5.25%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MYGN Yearly Revenue VS EstimatesMYGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
MYGN Yearly EPS VS EstimatesMYGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 57.08, MYGN can be considered very expensive at the moment.
Based on the Price/Earnings ratio, MYGN is valued cheaply inside the industry as 93.12% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 28.79. MYGN is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 94.07, which means the current valuation is very expensive for MYGN.
Based on the Price/Forward Earnings ratio, MYGN is valued cheaper than 91.01% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.38. MYGN is valued rather expensively when compared to this.
Industry RankSector Rank
PE 57.08
Fwd PE 94.07
MYGN Price Earnings VS Forward Price EarningsMYGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYGN Per share dataMYGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

MYGN's earnings are expected to grow with 53.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.76%
EPS Next 3Y53.71%

More info and screens

0

5. Dividend

5.1 Amount

MYGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MYRIAD GENETICS INC

NASDAQ:MYGN (4/25/2025, 8:25:17 PM)

After market: 7.42 0 (0%)

7.42

+0.05 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24 2025-02-24/amc
Earnings (Next)05-01 2025-05-01/amc
Inst Owners104.25%
Inst Owner Change-48.88%
Ins Owners2.21%
Ins Owner Change3.86%
Market Cap683.90M
Analysts70.43
Price Target15.54 (109.43%)
Short Float %5.96%
Short Ratio4.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)101.18%
Min EPS beat(2)-2.9%
Max EPS beat(2)205.26%
EPS beat(4)3
Avg EPS beat(4)198.46%
Min EPS beat(4)-2.9%
Max EPS beat(4)500.81%
EPS beat(8)6
Avg EPS beat(8)133.36%
EPS beat(12)9
Avg EPS beat(12)102.73%
EPS beat(16)13
Avg EPS beat(16)96.48%
Revenue beat(2)0
Avg Revenue beat(2)-1.6%
Min Revenue beat(2)-2.43%
Max Revenue beat(2)-0.76%
Revenue beat(4)2
Avg Revenue beat(4)0.1%
Min Revenue beat(4)-2.43%
Max Revenue beat(4)2.44%
Revenue beat(8)4
Avg Revenue beat(8)0.5%
Revenue beat(12)7
Avg Revenue beat(12)0.25%
Revenue beat(16)9
Avg Revenue beat(16)1.25%
PT rev (1m)-17.66%
PT rev (3m)-29.56%
EPS NQ rev (1m)6%
EPS NQ rev (3m)-2310.29%
EPS NY rev (1m)12.78%
EPS NY rev (3m)-23.53%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-5.93%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-3.51%
Valuation
Industry RankSector Rank
PE 57.08
Fwd PE 94.07
P/S 0.82
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB 5.08
EV/EBITDA N/A
EPS(TTM)0.13
EY1.75%
EPS(NY)0.08
Fwd EY1.06%
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS9.09
BVpS8.03
TBVpS1.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.73%
ROE -17.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.89%
FCFM N/A
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
F-Score5
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.53%
Cap/Sales 3.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.96
Quick Ratio 1.78
Altman-Z 0.96
F-Score5
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)84.3%
Cap/Depr(5y)59.15%
Cap/Sales(3y)6.65%
Cap/Sales(5y)4.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)146.43%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-39.33%
EPS Next 2Y45.76%
EPS Next 3Y53.71%
EPS Next 5Y33.97%
Revenue 1Y (TTM)11.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%7.12%
Revenue Next Year0.79%
Revenue Next 2Y4.51%
Revenue Next 3Y5.51%
Revenue Next 5Y5.25%
EBIT growth 1Y34.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.12%
EBIT Next 3Y58.99%
EBIT Next 5Y55.69%
FCF growth 1Y79.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.16%
OCF growth 3YN/A
OCF growth 5YN/A